Michael S. Baker

Michael S. Baker

Auto-generated profile, based on publicly available information

Michael S. Baker

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMichael S. Baker
Michael S. Baker
SVSara Venturini
Sara Venturini
CLCaroline Lindblad
Caroline Lindblad
JHJoshua M. Heihre
Joshua M. Heihre
ITIvan Timofeev
Ivan Timofeev
AHAdel Helmy
Adel Helmy
Objective: We aimed to compare the prevalence and multimodal associations of mitochondrial dysfunction as defined by published cerebral-microdialysis-based criteria versus our novel multimodality-monitoring-based criteria in acute traumatic brain injury patients. Methods: We retrospectively analyzed neurocritical care monitoring data from 619 acute traumatic brain injury patients. Monitoring modalities included cerebral microdialysis, intracranial pressure, brain tissue oxygenation, cerebral perfusion pressure, and the pressure reactivity index. The cerebral-microdialysis-based criteria we compared combine an elevated lactate/pyruvate ratio (25 or 30) with raised concentrations of lactate (2.5 mM) or pyruvate (70 μM or 120 μM). Our multimodality-monitoring-based criteria comprise a consistent lactate/pyruvate ratio > 25 with intracranial pressure ≤ 20 mmHg, brain tissue oxygenation ≥ 15 mmHg, a pressure reactivity index ≤ 0.3, and cerebral glucose ≥ 1.0 mM. Results: Across 592 analyzable patients, a lactate/pyruvate ratio > 25 was common, with a median prevalence of 48.9% (41.5% with consistency) and a U-shaped, bimodal distribution. A lactate/pyruvate ratio > 25 was associated with lower glucose and higher glycerol, and when accompanied by high pyruvate (> 120 μM), this derangement was further distinguished by higher glutamate and cerebral perfusion pressure. Using multimodal criteria on a cohort of 268 patients, consistent mitochondrial dysfunction was identified in 25.7% to 41.0% of patients, often in the absence of other physiological derangements. Conclusions: Many acute traumatic brain injury patients constantly demonstrate neurometabolic derangements, among which clinical mitochondrial dysfunction is highly prevalent despite normal cerebral pressure, oxygenation, and perfusion. There is necessity for targeted, neurometabolic therapies in neurocritical care that address this abnormality.

13 April 2026 in Critical Care
Verified
Journal Article
Open access
PDF file
AHAdel Helmy
Adel Helmy
MBMichael S. Baker
Michael S. Baker
PCPatrick M. Chen
Patrick M. Chen
AQAoife Quinn
Aoife Quinn
IJIbrahim Jalloh
Ibrahim Jalloh
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson
Purpose: Secondary brain injury is a common cause of poor outcome after trauma, subarachnoid hemorrhage, and intracerebral hemorrhage, and optimizing treatment requires real-time insight into cerebral metabolism. Cerebral microdialysis (CMD) uniquely provides key related information, yet consensus on its use has not been updated since publication of the consensus statement from the 2014 International Microdialysis Forum. We aimed to assess expert consensus on the use of CMD in critical care and provide contemporary guidance to standardize practice and advance clinical implementation. Methods: We conducted a 3-round modified Delphi study with international experts in CMD and neurocritical care. Consensus was defined as ≥ 75% agreement among non-abstaining respondents, with a minimum of 30 non-abstaining respondents required per statement. Statements not reaching consensus were iteratively revised based on panelist feedback. Results: Forty of 67 invited experts (60%) from 9 countries participated. Sixty of 62 individual items achieved consensus (97%) across 9 domains: indications and patient selection, technical and procedural considerations, detecting deterioration and secondary injury, metabolic interpretation, treatment algorithms, glucose management, sampling frequency, core reporting items, and barriers to clinical implementation. Conclusion: This consensus statement provides updated, evidence-informed recommendations for the use of CMD in critical care. The panel reaffirmed many core recommendations from the 2014 consensus while making targeted advances: cautious extension of guidance to intracerebral hemorrhage, comprehensive reporting guidance addressing frequently omitted elements (19 items vs. 6 in 2014), and identification of 10 key barriers to routine clinical adoption.

26 August 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
MBMichael S Baker
Michael S Baker
JHJoshua M Heihre
Joshua M Heihre
TKTomasz Kuliński
Tomasz Kuliński
CSClaudia A Smith
Claudia A Smith
BBBerfin Barlas
Berfin Barlas
AHAdel Helmy
Adel Helmy
Cerebral microdialysis (CMD) after traumatic brain injury (TBI) has focused on lactate/pyruvate ratio (LPR), overlooking lactate–pyruvate gradient (LPG, the linear regression slope within a time segment of CMD datapoints) as a proxy for anaerobic activity. We retrospectively applied changepoint detection to the linear lactate–pyruvate relationship (L = m P + b ) over time within patients from two independent CMD-monitored TBI cohorts (Cambridge, n = 510; Uppsala, n = 81), estimating per-segment LPG ( m ) and intercept ( b , capturing metabolic variance). In vitro, we tested whether rotenone-induced mitochondrial dysfunction increases LPG in hiPSC-derived neurons, as expected if LPG tracks anaerobic activity. In the Cambridge cohort, a median of two linear segments were identified per patient (median LPG = 19.83; median b = 0.54 mM). Between segments, LPR tracked LPG with heavy attenuation (β = 0.255). LPG was negatively associated with cerebral microdialysate glucose ( p < 0.001) and 6-month GOSE ( p = 0.039). Uppsala data confirmed pipeline robustness and replicated the LPG–glucose association ( p = 0.022). LPG was higher in rotenone-treated neurons than controls (32.9 vs 14.2, p < 0.001). LPG calculated per time segment provides a more accurate, outcome-associated proxy for anaerobic activity than datapoint-level LPR.